Digital PNG artwork · delivered by email | Secure checkout · no physical shipping
Hedi Raizer

Journal 6 min read

What is hepatic steatosis?

Hepatic steatosis is the accumulation of fat in the liver, formally known as metabolic dysfunction-associated steatotic liver disease (MASLD). This page explains the condition and reviews laboratory research on compounds

peptides-pro Editorial

What is hepatic steatosis?

Hepatic steatosis is the accumulation of excess fat within the liver. Its formal disease name is metabolic dysfunction-associated steatotic liver disease (MASLD), a term that replaced non-alcoholic fatty liver disease (NAFLD) and metabolic associated fatty liver disease (MAFLD) in recent nomenclature. MASLD is the most prevalent chronic liver disease worldwide and is strongly associated with obesity, insulin resistance, oxidative stress, and mitochondrial dysfunction [9]. The condition exists on a continuum; its progressive inflammatory form is metabolic dysfunction-associated steatohepatitis (MASH) [11].

Research into MASLD centres on several intersecting pathways, including the fibroblast growth factor 21 (FGF21)–PPARα axis, AMP-activated protein kinase (AMPK) signalling, GLP-1 and glucagon receptor (GCG) agonism, and gut microbial metabolism of dietary flavonoids [4][7][8][2].

Research Studies

Metformin–Dapagliflozin and IGF-1 in Male T2DM with MASLD

A 3-month, single-centre, prospective, randomized, parallel-controlled, open-label trial is investigating the effects of metformin combined with dapagliflozin on serum IGF-1 levels in male patients with type 2 diabetes mellitus (T2DM) and MASLD. Eighty-four eligible male patients (aged 30–60 years, HbA1c 7.0%–10.0%, CAP ≥248 dB/m, on stable metformin monotherapy for ≥8 weeks) are randomized 1:1 to continue metformin alone or receive metformin plus dapagliflozin 10 mg/day for 12 weeks. The primary endpoint is the change in serum IGF-1 from baseline to 3 months between groups [1].

Bifidobacterium pseudocatenulatum and Hesperidin Conversion in Aging Mice

Dietary flavonoids often require microbial metabolism to generate bioactive metabolites. Hesperidin, a citrus flavanone glycoside, has limited intestinal absorption and depends on gut microbial biotransformation to yield its active aglycone, hesperetin. Hesperetin activates CDGSH iron-sulfur domain 2 (CISD2), a pro-longevity gene whose expression declines with age. A probiotic strain, Bifidobacterium pseudocatenulatum CL256B, efficiently converts hesperidin to hesperetin via coordinated α-L-rhamnosidase and β-glucosidase activity and improves metabolic dysfunction in aging mice [2].

Lactobacillus acidophilus and Hepatic Dysregulation in MASLD and Diabetes Models

Gut microbial dysbiosis has been implicated in MASLD and diabetes. Based on validation of disease-associated microbial patterns in a clinical cohort, Lactobacillus acidophilus was selected as a candidate strain and investigated across multiple complementary models, including Western diet, fructose-palmitate-cholesterol diet, high-fat diet, and leptin-deficient ob/ob mice. L. acidophilus supplementation attenuated hepatic steatosis and inflammatory injury in multiple models [3].

FGF21–PPARα Axis and COX-2-Mediated Arachidonic Acid Metabolism in Liver Steatosis

MASLD is associated with disturbances in arachidonic acid (AA) metabolism. Fibroblast growth factor 21 (FGF21) was identified as a suppressor of hepatic cyclooxygenase-2 (COX-2) in MASLD. Although both FGF21 and COX-2 were elevated in steatotic livers, FGF21 deficiency further augmented hepatic COX-2 expression in mice fed a high-fat diet, leading to dysregulated AA metabolism, excessive prostaglandin E2 (PGE2) production, aggravated inflammation, and oxidative stress. Inhibition of COX-2-mediated AA metabolism by the FGF21–PPARα axis alleviated liver steatosis [4].

Mazdutide in T2DM and Moderate-to-Severe NAFLD After Semaglutide

A multicentre, prospective, randomized controlled investigator-initiated trial is evaluating the efficacy and safety of switching to mazdutide therapy in patients with T2DM and moderate-to-severe NAFLD who have achieved glycemic control. Chinese patients with T2DM are susceptible to visceral fat accumulation, which increases the risk of cardiometabolic diseases and mortality. MAFLD is highly prevalent among Chinese T2DM patients, and the coexistence of T2DM and moderate-to-severe fatty liver significantly elevates liver-related and all-cause risks [5].

Butyrate or Intensive Lifestyle Modification in Type 1 Diabetes and MASLD

MASLD is highly prevalent in individuals with type 1 diabetes (T1D) and is associated with increased cardiovascular and metabolic risk. Evidence regarding effective therapeutic strategies for MASLD in T1D remains scarce. Lifestyle modification has shown benefits in obesity and type 2 diabetes, whereas butyrate, a microbiota-derived short-chain fatty acid, has emerged as a potential therapeutic approach because of its anti-inflammatory and metabolic effects. A study aims to evaluate the efficacy of intensive lifestyle modification, butyrate supplementation, or their combination on hepatic steatosis in individuals with T1D [6].

SLC31A1-Dependent Copper Accumulation and AMPKα1 Inactivation in T2D Mice and Hepatocytes

Hepatic insulin resistance and fat accumulation are common features of metabolic syndrome, obesity, and type 2 diabetes. The role of the copper importer SLC31A1 in diabetes-associated hepatic metabolic disorders was studied in HFD/STZ-induced T2D mice and in glucosamine (GlcN)- or oleic acid-treated hepatocytes. Hepatic SLC31A1 expression and copper accumulation were enhanced in these models. Hepatocyte SLC31A1-dependent copper accumulation contributed to hepatic glucose and lipid metabolic disturbances through AMPKα1 inactivation [7].

Mazdutide Pre-hepatectomy Rehabilitation in Obese MASLD-Complicated Living Liver Donors

A study is evaluating the efficacy and safety of a short-term (12-week) prehabilitation strategy combining mazdutide (a GLP-1/GCG receptor dual agonist) with lifestyle optimization, compared to lifestyle optimization alone, in potential living liver transplantation donors with MASLD. Overweight or obese individuals who intend to donate a portion of their liver but are temporarily disqualified due to hepatic steatosis are recruited across multiple clinical centres. Participants are randomly assigned 1:1 to either the experimental group (mazdutide subcutaneous injection once weekly plus standardized lifestyle optimization) or the control group [8].

Copper Deficiency and Hepatic Steatosis in High-Fat-Fed Mice

A copper-deficient diet increased the development of hepatic steatosis, oxidative stress, and mitochondrial dysfunction in mice fed a high-fat diet [9].

Hepassocin and Age-Related Liver Senescence

Liver aging significantly impairs hepatic function and regenerative capacity. Hepassocin (HPS), a hepatokine with known hepatoprotective functions, prevents age-related liver senescence and facilitates liver regeneration by activating AMPK [10].

Semaglutide and Tirzepatide for MASH

MASLD and its progressive form, MASH, are increasingly prevalent conditions closely linked to obesity, insulin resistance, and cardiometabolic diseases. Although lifestyle modification remains a cornerstone of management, pharmacological options are evolving. Semaglutide and tirzepatide have been investigated for the treatment of MASH [11].

Alpha-Lipoic Acid and High-Fat Diet-Induced Hepatic Steatosis

Alpha-lipoic acid (ALA), a naturally occurring organosulfur compound with potent antioxidant activity, shows hepatoprotective potential. Dietary ALA supplementation alleviates high-fat diet-induced hepatic steatosis and inflammation by remodelling the gut microbiota and restoring the primary bile acid pool [12].

If you are reading this for personal health reasons

The compounds and interventions described on this page are sold for laboratory research only. We do not provide dosing or medical guidance. Anyone considering a compound for themselves should speak to a licensed clinician.

Sources

WhatsApp